Arrowhead Pharmaceuticals (ARWR) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for March 19, 2026, will be held virtually, allowing shareholders to vote and submit questions online.

• Shareholders will vote on the election of seven directors, an advisory say-on-pay vote, approval of an amended incentive plan, and ratification of KPMG as auditors.

• The company reported significant business development, including major licensing deals, clinical milestones, and regulatory approvals for key products in 2025.

• Financial highlights include $829.4 million in revenue for fiscal 2025, a net loss of $1.6 million, and a strong cash position of $919.4 million at year-end.

Voting matters and shareholder proposals

• Proposals include: election of seven directors, advisory vote on executive compensation, approval of the Amended and Restated 2021 Incentive Plan, and ratification of KPMG as independent auditors.

• Shareholders may submit proposals for the 2027 meeting by September 28, 2026, and director nominations between November 19 and December 19, 2026.

• Proxy access allows shareholders with 3% ownership for 3 years to nominate up to 20% of the board.

Board of directors and corporate governance

• Board consists of a majority of independent directors, with a combined Chair/CEO and a Lead Independent Director.

• Board committees (Audit, Compensation, Nomination) are fully independent and meet regularly.

• Board diversity includes two female directors and one from an underrepresented community.

• Board oversees risk management, strategy, and ESG initiatives, with designated oversight for environmental and social responsibility.